Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)
The DOI matches its Crossref record; 100 of the 120 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The identification by Abifadel et al. in 2003 of the first mutations of PCSK9 was the major breakthrough in the cholesterol field that led to a new therapeutic target. This discovery paved the way to new lipid lowering drugs reducing LDL-cholesterol levels through the inhibition of PCSK9. Two anti-PCSK9 monoclonal antibodies have received FDA and EMA approvals: Alirocumab and Evolocumab. Areas covered: This article reviews the different strategies that are pursued to modulate the functional activity of PCSK9 for lowering LDL-cholesterol levels. It also provides a brief overview of the patents related to PCSK9 from 2011 until the end of 2015. This review is addressed to researchers from academia and pharmaceutical companies who are engaged in PCSK9 research/cholesterol regulation. Readers will gain an up-to-date overview of the different strategies that have been investigated to reduce PCSK9, focusing on anti-PCSK9 monoclonal antibodies and the related clinical trials. Expert opinion: Anti-PCSK9 antibodies are a new class of lipid lowering drugs with promising results in reducing LDL-cholesterol. Long-term ongoing studies investigating on a large scale the efficacy and safety of the anti-PCSK9 antibodies and their cardiovascular outcomes are eagerly awaited.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL-C level was −62%; the treatment effect remained consistent over a period of 78 weeks [83].”
MethodLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191 · cited 3×
“subtilisin and yeast kexin, this last family member was then renamed proprotein convertase subtilisin kexin 9, or PCSK9 [1,2].”
BackgroundSelf-citationRaal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61399-4 · Cited by 756
Raal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720 · cited 1×
“5% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe [100].”
Background
Cited by
Genetic and molecular architecture of familial hypercholesterolemia
Abifadel, M., & Boileau, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13577 · Cited by 178
Self-citationGenetic and microbiome influence on lipid metabolism and dyslipidemia
Matey-Hernandez, M. L., Williams, F. M. K., Potter, T., Valdes, A. M., Spector, T. D., & Menni, C. (2018) · Physiological Genomics · doi:10.1152/physiolgenomics.00053.2017 · Cited by 130
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 116
Self-citationTargeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Katzmann, J. L., Gouni-Berthold, I., & Laufs, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.595819 · Cited by 87
Small molecules as inhibitors of PCSK9: Current status and future challenges
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85
Seidah, N. G. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100130 · Cited by 72
Self-citationBen Djoudi Ouadda, A., Gauthier, M.-S., Susan-Resiga, D., Girard, E., Essalmani, R., Black, M., Marcinkiewicz, J., Forget, D., Hamelin, J., Evagelidis, A., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313247 · Cited by 57
Self-citationKhoury, P. E., Elbitar, S., Ghaleb, Y., Khalil, Y. A., Varret, M., Boileau, C., & Abifadel, M. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0684-8 · Cited by 51
Self-citationProprotein convertase inhibition: Paralyzing the cell’s master switches
Klein–Szanto, A. J., & Bassi, D. E. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.04.027 · Cited by 51
Elbitar, S., Susan‐Resiga, D., Ghaleb, Y., Khoury, P. E., Peloso, G. M., Stitziel, N. O., Rabès, J., Carreau, V., Hamelin, J., Ouadda, A. B. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20281-9 · Cited by 41
Self-citationAlirocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305354 · Cited by 38
Khoury, P. E., Roussel, R., Fumeron, F., Khalil, Y. A., Velho, G., Mohammedi, K., Jacob, M., Steg, P. G., Potier, L., Ghaleb, Y., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13181 · Cited by 35
Self-citationSeidah, N. G. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.01.015 · Cited by 14
Self-citationFarnier, M. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000356 · Cited by 13
PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
Momtazi‐Borojeni, A. A., Pirro, M., Xu, S., & Sahebkar, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211027125245 · Cited by 12
Evolocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1365134 · Cited by 9
The Biology and Clinical Implications of PCSK7
Sachan, V., Susan‐Resiga, D., Lam, K., & Seidah, N. G. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae031 · Cited by 9
Self-citationPCSK9 inhibitors: a patent review 2018-2023
Fassi, E. M. A., Citarella, A., Albani, M., Milano, E. G., Legnani, L., Lammi, C., Silvani, A., & Grazioso, G. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2340569 · Cited by 8
Gupta, J., & Gupta, R. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467216666221202144813 · Cited by 6
Anti-inflammatory and Atheroprotective Properties of Omega-3 Polyunsaturated Fatty Acids
Sorokin, A. V., Yang, Z. H., & Remaley, A. T. (2016) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000478 · Cited by 2
Starup‐Linde, J., & Gregersen, S. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_13-1 · Cited by 1
Starup‐Linde, J., & Gregersen, S. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_13-2 · Cited by 1
Starup‐Linde, J., & Gregersen, S. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_13 · Cited by 1
La mejoría del pronóstico cardiovascular de la diabetes mellitus tipo 2 ¿es una realidad?
Ruiz‐Hurtado, G., Vigil, L., & Ruilope, L. M. (2016) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2016.10.001
Elbitar, S. (2018) · theses.fr (ABES) · doi:10.70675/0d164341z4f5cz438cz9edazc7cc446db7a4
Self-citationHypercholestérolémie familiale : recherche de nouveaux gènes et étude des formes polygéniques
Ghaleb, Y. (2017) · theses.fr (ABES) · doi:10.70675/ab0b16eez4c40z4cb7zb42fzb7740e0c98ea
Self-citationStarup‐Linde, J., & Gregersen, S. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_13
BindingDB (2021) · UC San Diego · doi:10.7270/q2j38wzz
Khalil, Y. A. (2021) · theses.fr (ABES) · doi:10.70675/1964fe3fz37bfz493azb98czc7caecac12cf
Metadata
- Authors
- Elbitar, S., Khoury, P. E., Ghaleb, Y., Rabès, J.-P., Varret, M., Seidah, N. G., Boileau, C., & Abifadel, M.
- Affiliations
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Montreal Clinical Research Institute (CA)
- ,
- Corresponding author
- Abifadel, Marianne
- ORCID
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2016-07-12
- Volume
- 26
- Issue
- 12
- Pages
- 1377-1392
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2466927139
- Semantic Scholar
- 23a1de473e3572cf5767b7f62869b431f0b74572
- Cited by
- 29
- References
- 120
- Citations by year
- 2024: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 7 · 2017: 5 · 2016: 4
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Therapeutic Patents (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fondation-Leducq (FLQ # 13 CVD 03)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9 inhibitors, PCSK9, anti-PCSK9 monoclonal antibodies, alirocumab, evolocumab, LDL cholesterol lowering, lipid-lowering drugs, PCSK9 mutations, cardiovascular outcomes, patent analysis
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Animals, Antibodies, Monoclonal, Anticholesteremic Agents, Humans, Cholesterol, LDL, Mutation, Patents as Topic, Drug Design, Dyslipidemias, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.